Related Experiment Videos
A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption
R F Tyndale1, M L Pianezza, E M Sellers
1Centre for Addictions and Mental Health, Toronto, Ontario, Canada. r.tyndale@utoronto.ca
Abstract:
Nicotine is the primary compound present in tobacco that is responsible for establishing and maintaining tobacco dependence; dependent smokers adjust their smoking behavior to maintain peripheral and central nicotine levels. CYP2A6 is the enzyme responsible for the majority of the inactivation of nicotine in humans. This enzyme is also responsible for activating tobacco-related procarcinogens such as the nitrosamines. This paper outlines how genetic variation in the CYP2A6 gene may protect individuals from becoming nicotine-dependent smokers, and if dependent, how impairment of the CYP2A6 gene function decreases the number of cigarettes consumed by smokers (Pianezza M, Sellers EM, Tyndale RF. 1998. A common genetic defect in nicotine metabolism decreases smoking. Nature 393(6687):750). We also discuss recent findings which suggest that mimicking this gene defect by inhibiting CYP2A6 decreases nicotine metabolism and smoking. Further research is needed in order to improve our understanding of how genetic variation in CYP2A6 alters the risk for nicotine dependence and lowers nicotine consumption. This includes a better understanding of how the genetic variants alter nicotine metabolism in vivo in males and females as well as the role of CYP2A6 genetic variation in risk for tobacco-related cancers. In addition we need to gain a better understanding of how manipulating this enzyme could be used therapeutically in prevention and treatment of smoking as well as in exposure reduction.
Insights
Genetic variations in the CYP2A6 enzyme, which metabolizes nicotine, can reduce smoking. Inhibiting this enzyme also decreases nicotine metabolism and smoking, suggesting therapeutic potential.
Area of Science:
- Pharmacogenomics
- Tobacco Dependence Research
- Enzyme Kinetics
Background:
- Nicotine dependence is driven by nicotine levels, with the CYP2A6 enzyme crucial for nicotine metabolism.
- CYP2A6 also activates tobacco procarcinogens, linking its function to cancer risk.
- Genetic variations in CYP2A6 influence nicotine metabolism and smoking behavior.
Purpose of the Study:
- To explore how CYP2A6 genetic variations affect nicotine dependence and consumption.
- To review evidence on CYP2A6 inhibition as a strategy to reduce smoking.
- To identify areas for future research on CYP2A6's role in smoking and cancer.
Main Methods:
- Review of existing literature on CYP2A6 genetics and nicotine metabolism.
- Analysis of studies investigating the impact of CYP2A6 variants on smoking behavior.
- Discussion of findings related to CYP2A6 inhibition and its effects on smoking.
Main Results:
- Common genetic defects in CYP2A6 are associated with reduced nicotine dependence and lower cigarette consumption.
- Inhibiting CYP2A6 activity mimics genetic defects, leading to decreased nicotine metabolism and smoking.
- CYP2A6 genetic variation impacts nicotine metabolism differently in males and females.
Conclusions:
- CYP2A6 genetic variations play a significant role in modulating nicotine dependence and smoking behavior.
- Targeting CYP2A6 offers a potential therapeutic strategy for smoking cessation and prevention.
- Further research is needed to fully elucidate CYP2A6's role in tobacco-related diseases and treatment.